CanSino Biologics (06185.HK): NDA for Td5cp, a Diphtheria-Tetanus-Pertussis Vaccine for Adolescents and Adults, Accepted for Review
NewTimeSpace News: On August 16, 2026, CanSino Biologics (06185.HK) announced that the NDA for its self-developed Td5cp (a booster diphtheria-tetanus-pertussis vaccine for populations aged 6 years and above) for adolescents and adults has been accepted for review by the NMPA and has been granted priority review status.
CanSino Biologics stated that Td5cp is a five-component pertussis-containing vaccine, which adds two additional pertussis antigen components compared to the company's already approved DT3cP vaccine for infants. Each antigen can be separately purified and formulated at determined ratios, ensuring batch-to-batch consistency in product quality.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CanSino Biologics (06185.HK): Supplementary Application for Menhyxin® Accepted, Age Eligibility to Be Expanded to 17 Years Old
- CanSino Biologics (06185.HK): MCV4 Vaccine Granted Registration Certificate in Argentina
- Cansinobio (06185.HK): Td5cp Vaccine for Adolescents & Adults Included in Priority Review
